Clinical trials have also explored the combination of 4-1BB agonists with immunotherapy or chemotherapy and yielded diverse outcomes, encompassing heightened anti-tumor efficacy and improved survival rates in select cases 150-152. Here, TNFRSF9 is linked to neoplasm.